EGFR/ALK野生型晚期NSCLC患者血清miR-499 miR-144-3p变化及对预后的预测价值  

Serum miR-499 and miR-144-3p Changes in EGFR/ALK Wild-Type Advanced NSCLC Patients and Their Predictive Value for Prognosis

作　　者：谷振芳[1] 徐保彬[1] 李伟[1] 张春梅[1] 周亚青 GU Zhenfang;XU Baobin;LI Wei(Affiliated Hospital of Jining Medical University,Shandong Jining 272000,China)

机构地区：[1]济宁医学院附属医院,山东济宁272000

出　　处：《河北医学》2023年第11期1816-1820,共5页Hebei Medicine

基　　金：山东省医药卫生科技发展计划项目,(编号:2019WS365)。

摘　　要：目的:分析表皮生长因子受体(EGFR)/间变性淋巴瘤激酶(ALK)野生型晚期非小细胞肺癌(NSCLC)患者血清微小RNA(miR)-499、miR-144-3p变化,并评估其对预后的预测价值。方法:收集2018年1月至2020年我院收治的107例EGFR/ALK野生型晚期NSCLC患者临床资料(NSCLC组),另取同期健康体检者107例作为对照组,采用实时荧光RCR技术检测血清miR-499、miR-144-3p表达,比较其在两组中的差异,并评估不同临床病理特征晚期NSCLC患者血清miR-499、miR-144-3p表达的变化;以出院时为随访起点,2023年1月为截止时间,死亡为终点事件,以大于等于平均值作为高表达的标准,分别比较miR-499、miR-144-3p高表达与低表达的晚期NSCLC患者预后生存率。结果:NSCLC组血清miR-499[(0.74±0.18)vs(1.05±0.20)]、miR-144-3p相对表达量[(0.82±0.19)vs(1.22±0.21)]均低于对照组(P<0.05)。晚期NSCLC患者中,Ⅳ期患者血清miR-499[(0.64±0.17)vs(0.86±0.21)]、miR-144-3p相对表达量[(0.71±0.16)vs(0.95±0.22)]低于ⅢB及ⅢC期者(P<0.05),低分化者则低于中高分化者[(0.63±0.16)vs(0.85±0.21),(0.70±0.15)vs(0.94±0.22),P<0.05]。晚期NSCLC患者随访时间为4~56个月,中位随访时间34个月,血清miR-499高表达者生存率明显高于低表达者(P<0.05),血清miR-144-3p高表达者生存率明显高于低表达者(P<0.05)。结论:miR-499、miR-144-3p在EGFR/ALK野生型晚期NSCLC患者血清中呈低表达,Ⅳ期及低分化者表达更低,且表达水平对预后生存率有一定预测价值。Objective:To analyze the variations in serum microRNA(miR-499)and miR-144-3p among patients with advanced non-small cell lung cancer(NSCLC)of epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)wild-type,and evaluate their predictive value for prognosis.Methods:Clinical data were collected from 107 patients with EGFR/ALK wild-type advanced NSCLC who were admitted to the hospital between January 2018 and 2020(NSCLC group).Additionally,107 healthy subjects who underwent physical examinations during the same period were selected as the control group.Real-time fluorescence RCR technology was employed to measure the expression of serum miR-499 and miR-144-3p.Differences between the two groups were compared,and changes in serum miR-499 and miR-144-3p expressions were assessed across patients with advanced NSCLC exhibiting various clinicopathological characteristics.Follow-up began at discharge and ended in January 2023,considering death as the endpoint event.The prognostic survival rate was compared between advanced NSCLC patients with high and low expressions of miR-499 and miR-144-3p,using an expression level greater than the average value as the criterion.Results:In the NSCLC group,relative expression levels of serum miR-499[(0.74±0.18)vs(1.05±0.20)]and miR-144-3p[(0.82±0.19)vs(1.22±0.21)]were significantly lower compared to the control group(P<0.05).Among patients with advanced NSCLC,the relative expression levels of serum miR-499[(0.64±0.17)vs(0.86±0.21)]and miR-144-3p[(0.71±0.16)vs(0.95±0.22)]were lower in stage IV patients compared to stageⅢB andⅢC patients(P<0.05).Furthermore,patients with lower differentiation exhibited lower expression levels compared to those with moderate-to-high differentiation[(0.63±0.16)vs(0.85±0.21),(0.70±0.15)vs(0.94±0.22),P<0.05].The follow-up duration for advanced NSCLC patients ranged from 4 to 56 months,with a median follow-up period of 34 months.Patients with high serum miR-499 expression had a significantly higher survival rate compared to tho

关 键 词：非小细胞肺癌 晚期 EGFR/ALK野生型 miR-499 miR-144-3p 预后 

分 类 号：R734.2[医药卫生—肿瘤]